The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CCXI, PRVB and WPG
Back to Newsroom
Mentioned in this Article

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CCXI, PRVB and WPG

Tuesday, June 22, 2021 7:15 PM
Share this article now
Topic:
Lawsuits
The Klein Law Firm

NEW YORK, NY / ACCESSWIRE / June 22, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

ChemoCentryx, Inc. (NASDAQ:CCXI)
Class Period: November 26, 2019 - May 6, 2021
Lead Plaintiff Deadline: July 6, 2021

During the class period, ChemoCentryx, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis; (2) the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan; (3) these issues presented a substantial concern regarding the viability of ChemoCentryx's New Drug Application ("NDA") for avacopan for the treatment of ANCA-associated vasculitis; and (4) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in CCXI: http://www.kleinstocklaw.com/pslra-1/chemocentryx-inc-loss-submission-form?id=17104&from=1

Provention Bio, Inc. (NASDAQ:PRVB)
Class Period: November 2, 2020 - April 8, 2021
Lead Plaintiff Deadline: July 20, 2021

Throughout the class period, Provention Bio, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) the teplizumab Biologics License Application ("BLA") was deficient in its submitted form and would require additional data to secure U.S. Food and Drug Administration approval; (ii) accordingly, the teplizumab BLA lacked the evidentiary support the Company had led investors to believe it possessed; (iii) the Company had thus overstated the teplizumab BLA's approval prospects and hence the commercialization timeline for teplizumab; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times. 

Learn about your recoverable losses in PRVB: https://www.kleinstocklaw.com/pslra-1/provention-bio-inc-loss-submission-form?id=17104&from=1

Washington Prime Group, Inc. (NYSE:WPG)
Class Period: November 5, 2020 - March 4, 2021
Lead Plaintiff Deadline: July 23, 2021

The WPG lawsuit alleges that Washington Prime Group, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) WPG's financial condition was deteriorating substantially; (2) as a result, there was substantial uncertainty about the Company's ability to meet its capital structure obligations as they became due; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in WPG: https://www.kleinstocklaw.com/pslra-1/washington-prime-group-inc-loss-submission-form?id=17104&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

Back to Newsroom
Copyright 2021 © ACCESSWIRE. All rights reserved. Privacy Policy  |   Terms and Conditions